CD30 is a cytokine receptor belonging to the tumor necrosis factor superfamily (TNFRSF8) that acts as a regulator of apoptosis. The presence of CD30 antigen is important in the diagnosis of Hodgkin's disease and anaplastic large cell lymphoma. There have been sporadic reports of CD30 expression in non-lymphoid tumors, including malignant mesothelioma. Given the remarkable success of brentuximab vedotin, an antibody-drug conjugate directed against CD30 antigen, in lymphoid malignancies, we undertook a study to examine the incidence of CD30 in mesothelioma and to investigate the ability to target CD30 antigen in mesothelioma. 
an advanced stage. Mesothelioma is associated with occupational asbestos exposure in most industrialized countries (1). Many emerging countries have yet to prohibit asbestos usage, which predicts that a great number of the patients will suffer from this disease in the future. In addition, there is also growing concern that the widespread use of nano-sized particles for medical and industrial purposes may create new risks for developing mesothelioma. Treatment for advanced malignant mesolthelioma is comprised of combination chemotherapy containing platinum and pemetrexed (2) . Since approval of this regimen for mesothelioma there have been no therapeutic advances for the treatment of this disease. Thus, there is an urgent need to develop new therapeutic strategies against this disease.
Antibody-based therapies and immunotoxins have shown remarkable therapeutic activities in various tumors and might represent a promising approach against mesothelioma (2, 3) . This approach targets antigens specifically expressed on cancerous cells, resulting in an increased therapeutic efficacy with minimal systemic toxicity. CD30 is a member of the tumor necrosis factor receptor super family (TNFRSF8) and is highly expressed in lymphoma with limited expression in healthy tissues, making it an ideal target for antibody-based therapies (4-8).
Recently, in clinical trials for relapsed/refractory Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) (9, 10), brentuximab vedotin demonstrated high response rates as a single agent leading to its accelerated approval by the Food and Drug Administration (FDA) for treatment of these lymphomas under the brand name Adcetris®. Brentuximab vedotin is an antibody-drug conjugate, which couples an anti-CD30 antibody (SGN-30) to the synthetic antitubulin agent MMAE (11).
Mesothelioma cells were seeded onto a glass-bottomed culture dish (MatTek Corp.). Cells were fixed with 4% formaldehyde diluted in PBS. After 1 h blocking with 1% bovine serum albumin in PBS, cells were incubated with a rabbit polyclonal anti-CD30 antibody (Novus Biologicals, NBP1-72175; 1:100) at room temperature for 2 h and washed three to four times with PBS.
Incubation with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes; 1:500) was done for 1 h at room temperature, followed by repeated washes using PBS. After subsequent staining of nuclei with 1 μM DRAQ5 in PBS for 30 min, confocal images were obtained on a Zeiss LSM510 NLO laser-scanning microscope using single-line (488 nm) or multitrack sequential excitation (488 and 633 nm). Images were acquired and processed with Zeiss LSM Image Browser software.
Flow cytometry analysis of CD30 expression
Expression of CD30 on the surface of mesothelioma cell lines was confirmed by FACS analysis, using a fluorescent dye conjugated secondary antibody Alexa Fluor 488-conjugated anti-rabbit IgG (Molecular Probes; 1:500). Mesothelioma cells were collected by centrifugation, fixed with ethanol by incubating at least 30 min at room temperature. Centrifuged again and supernatant decanted off. Cells were permeablized or non-permeabilized with or without Triton X-100 (0.1% in PBS) for 10 min, briefly centrifuged and the resulting supernatant removed. The cells were suspended in FACS buffer with or without diluted primary (rabbit polyclonal anti-CD30 antibody, NBP1-72175, 1:100) or secondary (Alexa Fluor 488-conjugated anti-rabbit IgG, 1:500) antibodies followed by 30 min incubation on ice. The stained cells were analyzed on a LSR II flow cytometer (BD Biosciences; San Jose, CA). FACS data were analyzed by using FlowJo software (Tree Star, Ashland, OR). 
Immunohistochemistry
The TMA slides were obtained from the National Mesothelioma Virtual Bank (NMVB) (http://mesotissue.org/). The slides were deparaffinized with xylene then transferred through graded ethanol to H2O. Endogenous peroxidase activity was blocked by a 10-min incubation in a 3% hydrogen peroxide solution. Antigen retrieval was performed by boiling the slides in a pressure cooker filled with a sodium citrate buffer (pH 6.0). After antigen retrieval, the slides were blocked using Background Sniper (Biocare, BS966M) for 20 min. The tissues were incubated with a mouse monoclonal anti-human CD30 antibody (Cell Marque/Clone Ber-H2) overnight at 4 o C. Bound antibody was detected as described previously (16 Multiple cores for a single tumor sample were viewed to determine the score.
Statistical Analysis
All the described experiments were done more than three times, and the data are presented as mean values ± SEM. P values were determined by t test using either Prism or SAS software (SAS Institute, Cary, NC). P < 0.05 was considered statistically significant.
Results

CD30 mRNA expression is high in mesothelioma tissues
We analyzed the gene expression patterns of CD 30 in all types of adult solid tumor cancer cell 
CD30 protein is expressed in mesothelioma tumors
We obtained tissue microarrays from the National Mesothelioma Virtual Bank (NMVB) to determine the level of CD30 staining in mesothelioma tumors by immuno-histochemistry.
Descriptive statistics for the entire cohort of analyzed samples, as well as for CD30+ samples, is given in Table 1 
mesothelioma cells in sub G1 phase was accompanied by a parallel increase in cells in the G2/M
phase. This is consistent with the anti-microtubule activity of the conjugated drug in brentuximab vedotin. MMAE, to produce mitotic arrest and G2/M blockade. Taken together, these results demonstrate that brentuximab vedotin treatment has an inhibitory effect on cell growth and survival in mesothelioma cells.
Discussion
The goal of this study was to determine the therapeutic potential of targeting CD30 with brentuximab vedotin in mesothelioma. We looked for CD30 expression in the largest cohort of mesothelioma tumors studied to date and found that only 15.6% (13 of 83 tumors) were positive for CD30 expression using an antisera routinely used in the diagnosis of Hodgkin's lymphoma. the typical C max and AUC for brentuximab vedotin after a single 1.8 mg/kg dose was approximately 32 μg/ml and 80 μg /ml/day, respectively, in a phase I study (Acedris® insert).
Second, the loss of mesothelioma cell viability after brentuximab vedotin treatment was associated with an increase in the proportion of cells in G2/M phase, as expected since the antibody conjugated toxin, MMAE, is a microtubule inhibitor. Third, there was no effect of brentuximab vedotin on a small cell lung cancer cell line, H526, suggesting therapeutic specificity. Rectangles show area magnified in image below. The 3+ core was scored higher than the 2+ core due to a greater area of positivity, not because of intensity. 
